FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of December 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
16 December 2024 07:00 GMT
Non-Executive Board Appointments
AstraZeneca
PLC announced today that Rene Haas and Birgit Conix have been
appointed as Non-Executive Directors with effect from 1 January
2025 and 1 February 2025 respectively.
Birgit
will become a member of the Audit Committee on appointment to the
Board.
Rene is
Chief Executive Officer of Arm. Birgit is Chief Financial Officer
of Sonova. Further biographical details are set out
below.
Michel
Demaré, Chair of AstraZeneca, said "I am confident Rene and
Birgit will be excellent additions to the AstraZeneca Board.
We look forward to welcoming them as we continue the process of
refreshing the Board in anticipation of four current Non-Executive
Directors reaching nine years' tenure in the coming
years.
"Rene
brings deep and broad knowledge of technology including data
science, computing and AI from his numerous years' experience in
the microprocessor, semiconductor and software engineering
industry, and experience of leading a large Cambridge, UK-based
technology company.
"Birgit's
financial and executive experience through successive CFO roles
over the last decade, together with her 15 years' experience of the
pharmaceutical industry prior to that, will enable her to
contribute to the Audit Committee's and Board's work from the
outset.
"Both
Rene and Birgit bring to AstraZeneca's Board significant
international experience in senior executive roles at large global
businesses."
Biographical details - Rene Haas
Rene
was appointed Chief Executive Officer and to the Arm Board in
February 2022. In September 2023, he led Arm's return to the
public markets with the most valuable IPO of the year. Prior
to becoming CEO, Rene was President of Arm's IP Product Groups
(IPG) from January 2017. Under his leadership, he transformed
IPG to focus on key solutions for vertical markets with a more
diversified product portfolio and increased investment in the Arm
software ecosystem. Rene joined Arm in October 2013 as Vice
President of Strategic Alliances and two years later was appointed
to the Executive Committee and named Arm's Chief Commercial Officer
in charge of global sales and marketing.
Before
joining Arm, Rene held several applications management,
applications engineering and product engineering roles, including
seven years at NVIDIA as Vice President and General Manager of its
computing products business. Prior to NVIDIA, Rene held
executive roles at Scintera Networks and Tensilica.
In
addition to his role as CEO of Arm, Rene also sits on the Boards of
Arm China and SoftBank Group.
Rene is
based in Silicon Valley, US and also spends significant time in the
major technology centres of the UK, Europe and Asia
Pacific.
Rene
earned his Bachelor of Science in Electrical and Electronics
Engineering from Clarkson University and is a graduate of the
Stanford University Graduate School of Business Executive Education
Program.
Biographical details - Birgit Conix
Birgit
joined Sonova and became Chief Financial Officer and a member of
the Management Board in 2021. She was previously Chief
Financial Officer and member of the Executive Board of TUI, a
global leader in tourism, from 2018 to 2021. Before joining
TUI, she was Chief Financial Officer of the Belgian media, cable
and telecommunications business Telenet Group from 2013 until
2018. Prior to that, she held various senior positions in
finance, strategy and business operations in the pharmaceuticals
and medical devices business units at Johnson & Johnson, and in
finance at Heineken, Tenneco and Reed Elsevier.
In
addition to her role as CFO of Sonova, Birgit is a member of the
Supervisory Board of ASML, one of the world's leading manufacturers
of chip-making equipment in the semiconductor industry, where she
is Chair of the ESG Committee and a member of the Audit
Committee.
Birgit
holds an MBA from the Booth School of Business, University of
Chicago and a Master of Science in Business Economics from the
University of Tilburg.
Except
as set out above, no disclosure obligations arise under paragraphs
(1) to (6) of UKLR 6.4.8 R of the UK Financial Conduct Authority's
Listing Rules in respect of these appointments.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based in
Cambridge, UK, AstraZeneca's innovative medicines are sold in more
than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For
details on how to contact the Investor Relations Team, please
click here. For Media
contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
16 December 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Nov 2024 to Dec 2024
AstraZeneca (PK) (USOTC:AZNCF)
Historical Stock Chart
From Dec 2023 to Dec 2024
